Skip to main
VALN

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE has received an optimistic boost in its commercial uptake assumptions for the VLA15 vaccine in Europe, aligning them with expectations in the US, thereby enhancing revenue potential. The strong immune responses reported following a third yearly booster of the VLA15 Lyme vaccine candidate in both adults and children suggest promising efficacy, which may lead to increased demand and sales. Despite a temporary suspension of the Ixchiq vaccine by the FDA, the overall earnings performance met expectations, indicating resilience in the company's financial health amid regulatory challenges.

Bears say

Valneva SE faces significant risks that contribute to a negative outlook, primarily due to potential clinical and regulatory setbacks, as well as commercial risks from competing vaccine products and lower-than-expected sales. Recent safety concerns regarding its chikungunya vaccine, Ixchiq, have raised doubts about its competitiveness against alternatives such as Bavarian Nordic's offering, despite claims of superior long-term protection. The company has also removed all projected U.S. sales for Ixchiq from its financial models and is anticipating limited commercial uptake in Europe, reflecting a cautious approach amid these challenges.

Valneva SE (VALN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.